OKYO Pharma Presents First-in-Human Urcosimod Data at ARVO 2026 Meeting

OKYO Pharma announced that its abstract has been accepted for presentation at ARVO 2026. Chief scientific officer Dr Raj Patil will present findings from the Phase 2a proof-of-concept clinical trial of urcosimod, a therapy for neuropathic corneal pain. The trial demonstrated clinically meaningful pain reduction and quality-of-life improvement in NCP patients. OKYO plans to advance urcosimod into a multicenter Phase 2b/3 trial with approximately 150 patients.